TNF and psoriasis: Briefly, TNFα levels did not decrease significantly with guselkumab treatment through Week 24, and baseline levels did not correlate with achievement of Week 24 clinical responses, apart from the Investigator’s Global Assessment of psoriasis score of 0/1 (clear/minimal) response among patients with an inadequate response to prior TNFi (TNFi-IR).39